Mechanistically-driven single biomarkers (e.g. PD-1/PD-L1 enrichment, tumor mutational burden, and <i>MGMT</i> methylation) are early opportunities for immunotherapy response prediction but have had inconsistent results across studies. This evidence concerns the gene MGMT and neoplasm.